Nkarta (NASDAQ:NKTX) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Nkarta (NASDAQ:NKTX) in a research report sent to investors on Thursday,Benzinga reports. The firm currently has a $18.00 price target on the stock. HC Wainwright also issued estimates for Nkarta’s Q4 2025 earnings at ($0.29) EPS and FY2029 earnings at ($0.99) EPS.

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Nkarta in a research note on Thursday. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $14.86.

Nkarta Stock Performance

Shares of NASDAQ NKTX opened at $2.00 on Thursday. The firm’s 50 day moving average price is $1.99 and its 200 day moving average price is $2.84. The firm has a market cap of $141.92 million, a P/E ratio of -1.06 and a beta of 0.90. Nkarta has a 1 year low of $1.31 and a 1 year high of $11.84.

Nkarta (NASDAQ:NKTX) last released its earnings results on Wednesday, March 26th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.06. As a group, equities analysts predict that Nkarta will post -1.7 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Paul J. Hastings sold 17,378 shares of Nkarta stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total transaction of $38,231.60. Following the sale, the chief executive officer now owns 319,859 shares in the company, valued at $703,689.80. This trade represents a 5.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 8.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in NKTX. Jefferies Financial Group Inc. lifted its holdings in Nkarta by 901.7% in the 4th quarter. Jefferies Financial Group Inc. now owns 2,504,219 shares of the company’s stock worth $6,236,000 after buying an additional 2,254,219 shares in the last quarter. Tang Capital Management LLC increased its position in shares of Nkarta by 252.9% during the fourth quarter. Tang Capital Management LLC now owns 2,293,719 shares of the company’s stock worth $5,711,000 after acquiring an additional 1,643,719 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Nkarta by 138.7% in the fourth quarter. JPMorgan Chase & Co. now owns 2,537,922 shares of the company’s stock worth $6,319,000 after acquiring an additional 1,474,560 shares in the last quarter. Wasatch Advisors LP lifted its stake in shares of Nkarta by 37.4% in the fourth quarter. Wasatch Advisors LP now owns 2,520,909 shares of the company’s stock worth $6,277,000 after acquiring an additional 686,229 shares in the last quarter. Finally, AWM Investment Company Inc. purchased a new position in Nkarta in the fourth quarter valued at about $996,000. 80.54% of the stock is currently owned by hedge funds and other institutional investors.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.